ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: View All • a b c d e f g h i j k [l] m n o p q r s t u v w x y z

Abstract Number: 0944

L-sepiapterin treatment reduces renal cortical gene expression associated with oxidative stress and fibrosis in NZM2410 murine lupus nephritis
Abstract Number: 0137

Landscape of Primary Antiphospholipid Syndrome: Clinical Spectrum, Serology, and Predictors of Damage in a Single Center Cohort of 233 Patients
Abstract Number: 1670

Large Retrospective Cohort Study Of Chronic Recurrent Multifocal Osteomyelitis: Disease Presentation, Clinical, And Laboratory Features
Abstract Number: 1121

Latent Class Analysis Identifies Distinct Phenotypes of Multisystem Immune-Related Adverse Events Predictive of Survival After Immune Checkpoint Inhibitors
Abstract Number: 1556

Latent Profiles of Parenchymal Abnormalities and Vascular Features Measured by Quantitative CT Identifies a Subgroup of Systemic Sclerosis Patients With a Greater Lung Function Decline Over Time
Abstract Number: 0181

Launch of the National Tele-Rheumatology Program (NTRP) to Expand Rheumatology Care to Rural Veterans
Abstract Number: 0005

LBL-047, A First-In-Class Anti-BDCA2/TACI Fusion Protein, Inhibits the Function of Both pDCs and B cells
Abstract Number: 0986

LBL-053, A Novel Anti-TL1A/p40 Bispecific Antibody for the Treatment of Autoimmune Disorders.
Abstract Number: 1001

LBL-057, a Novel ADCC Enhanced PD-1 Agonist VHH-Fc Antibody
Abstract Number: 0730

Levels of Disease Activity and Their Relationship With Health-Related Quality of Life In ANCA-Associated Vasculitis Patients: Data from the Almenara Vasculitis Cohort
Abstract Number: 1086

Leveraging Natural Language Processing to Uncover Real-World Trends in Cannabis Use from Clinic Notes in Electronic Health Records
Abstract Number: 1057

Leveraging Social Risk Factor Screening Infrastructure in Rheumatology Clinics to Respond to Rising Rates of Tuberculosis Among Individuals Experiencing Homelessness
Abstract Number: 0229

Leveraging the Electronic Medical Record to Improve the Rate of Discrete Data Collection in a Pediatric Rheumatology Clinic
Abstract Number: 0852

LEVI-04 Significantly Reduces Bone Marrow Lesions and Symptoms in Knee Osteoarthritis: Results from a Phase II RCT
Abstract Number: 2101

LEVI-04, a Novel Neurotrophin-3 Inhibitor, Demonstrates Clinically Meaningful Improvements in Pain and Physical Function across a Range of OA Outcomes, Including the Staircase-Evoked Pain Procedure (StEPP)
Abstract Number: 2650

LFA-REAL Outperforms SLEDAI and BILAG in Detecting Clinical Change in Lupus Activity
Abstract Number: 0494

LFD-200, an Antibody Drug Conjugate that Selectively Delivers a Glucocorticoid Payload to Immune Cells, Provides Sustained Anti-inflammatory Effects Without Systemic Toxicity in Non-human Primates
Abstract Number: 0131

Libman-Sacks Endocarditis in APS: A Case-Control Study of Clinical and Serologic Features
Abstract Number: PP13

Life Transitions and Their Impact on Patients
Abstract Number: 2309

Lifestyle behaviours and disease activity in patients with psoriatic arthritis: the Dutch south west psoriatic arthritis study
Abstract Number: 0371

Lifestyle Coaching in Psoriatic Arthritis: Pilot Findings from an Online eCoaching Program
Abstract Number: 2340

Lighten the Load: Artificial Intelligence Reveals Body Mass Index Outranks Treatment in One-Year Psoriatic Arthritis Outcomes—Findings from the SPEED Trial
Abstract Number: 1808

Lightsheet imaging with 3D analysis for wholistic assessment of synovial lymphatic vasculature within joints of murine models of arthritis
Abstract Number: 1488

Limited Concordance Between anti-dsDNA Assays and Association with Lupus Nephritis
Abstract Number: 0975

Linezolid prevents fibroblast activation and ameliorates tissue fibrosis by inhibition of mitochondrial translation
Abstract Number: 2063

Linking PROMIS scores to disease severity and treatment in dermatomyositis: a patient-centered evaluation
Abstract Number: 0437

Lipid Screening in Rheumatoid Arthritis: A Retrospective Cohort Study Highlighting Gaps in Cardiovascular Risk Prevention
Abstract Number: PP11

Lived Experience in Action: How Co-Creating a Psoriatic Arthritis Project Empowered My Journey as a Patient Advocate
Abstract Number: 1296

Liver Biopsy Findings in Pediatric SLE: A Large Tertiary Center Experience
Abstract Number: PP08

Living Well Despite the Challenges of Sjögren’s Disease and Systemic Lupus Erythematous: My Perspective as a Health Care Provider and Patient
Abstract Number: 0976

LMPTP Drives Fibrosis in Systemic Sclerosis via TGF-beta Signaling Activation
Abstract Number: 1537

Local Immune effector Cell-Associated Toxicity Syndrome (LICATS) in CAR T-cell treated patients with Autoimmune Disease
Abstract Number: 2276

Long-Term Cardiovascular Risk Following Tnfi vs Triple Therapy: A Post-hoc Analysis Integrating Randomized Clinical Trial and Electronic Health Record Data
Abstract Number: 2656

Long-term effect of selexipag in systemic sclerosis-associated digital ulcers: a case control, multicentre, observational study
Abstract Number: 1520

Long-Term Effects of Obinutuzumab on Kidney Function in Lupus Nephritis
Abstract Number: 2362

Long-Term Efficacy and Safety of Risankizumab for csDMARD-IR Patients With Active Psoriatic Arthritis: 244-Week Results From the KEEPsAKE 1 Trial
Abstract Number: 0582

Long-Term Efficacy and Safety of Tofacitinib in Active Axial Spondyloarthritis: Experience from a Tertiary Care Center in South India
Abstract Number: 0420

Long-term efficacy of intra-articular triamcinolone hexacetonide injections in juvenile idiopathic arthritis patients starting tumor necrosis factor inhibitor therapy: 48 weeks results from a randomized, open-label, blinded-assessor multicenter phase 4 trial – the MyJIA trial
Abstract Number: 1447

Long-term impact of secukinumab on the prevention of psoriatic arthritis in patients with psoriasis: a 5-year pooled analysis of the ERASURE, FIXTURE and SCULPTURE studies
Abstract Number: 1493

Long-Term Outcomes in Systemic Lupus Erythematosus Patients Infected with SARS-CoV-2: Variant-Specific Analysis of Pre-Delta/Delta and Omicron Periods
Abstract Number: 2279

Long-Term Prevention of RA in high-risk individuals after a 6-Month Placebo-Controlled Intervention with Abatacept -The ARIAA Trial
Abstract Number: 1432

Long-term Radiographic Progression in Early versus Established Axial Spondyloarthritis: A 12-Year Observational Study
Abstract Number: 1443

Long-Term Safety and Efficacy of Upadacitinib in Patients With Psoriatic Arthritis: 5-Year Results From the Phase 3 SELECT-PsA 1 Study
Abstract Number: 1676

Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients With Rheumatoid Arthritis: 7-Year Data From the SELECT-COMPARE Study
Abstract Number: 1454

Long-Term Safety and Tolerability of Bimekizumab Treatment Across Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update from the Phase 3 Studies
Abstract Number: 1456

Long-Term Safety of Tildrakizumab Through Week 208 in Patients With Psoriatic Arthritis: Results From the Phase 2b Open-Label Extension Study
Abstract Number: 2352

Long-Term Uveitis Rates with Bimekizumab Treatment Across Pooled Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update
Abstract Number: 2454

Longitudinal Analysis of B cell Remodeling in Systemic Lupus Erythematosus Following iPSC-Derived CAR T-cell Therapy
Abstract Number: 1958

Longitudinal analysis on imaging outcomes: should we use the individual scores from multiple readers or rather the consensus or average of readers?
Abstract Number: 1560

Longitudinal assessment of circulating fibroblast activation protein in systemic sclerosis-associated interstitial lung disease
Abstract Number: 2703

Longitudinal Changes on Cranial Magnetic Resonance Imaging in Relapsing Giant Cell Arteritis
Abstract Number: 1587

Longitudinal Clinical Response to JAK Inhibitors in Systemic Sclerosis: A Real-Life Multicentric Study Across Clinical Domains
Abstract Number: 2447

Longitudinal Disease Activity Trajectories in Patients with Systemic Lupus Erythematosus Treated with Belimumab
Abstract Number: 0401

Longitudinal Effectiveness of Abatacept in JIA: Results From an Ongoing JIA Registry
Abstract Number: 1289

Longitudinal Exploration of Pain and Disease Characteristics in Youth with Childhood-Onset Lupus
Abstract Number: 0823

Longitudinal model of paired peripheral blood CITE-seq and skin scRNA-seq data in juvenile systemic sclerosis (jSSc) patients following autologous stem cell transplant (ASCT) reveals reduced expression of SSc marker genes
Abstract Number: 0959

Longitudinal Multiomic Study of Skin, Peripheral Blood, and Serum: Serum Proteome Reflects the Disease Process at the End-organ Level and Predicts the Course of Modified Rodnan Skin Score
Abstract Number: 0774

Longitudinal peripheral blood multi-omic profiling in at-risk individuals uncovers immune signatures and predictive models for future rheumatoid arthritis conversion
Abstract Number: 0023

Longitudinal Proteomic Effects of Hydroxychloroquine in Individuals at Risk of Lupus: Differential Signatures in Progressors and Non-Progressors
Abstract Number: 1728

Longitudinal Proteomic Signatures for Prediction of Immune-Related Adverse Events during Immune Checkpoint Inhibitors therapy: A Machine Learning-Guided Prospective Biomarker Discovery Study
Abstract Number: 0297

Longitudinal Serum Proteomic Profiles – A Step Closer to Personalized Monitoring in Dermatomyositis
Abstract Number: 1644

Longitudinal Trajectory Models to Assess Pain and Risk of Difficult-to-Treat Rheumatoid Arthritis
Abstract Number: 2626

Lorecivivint Delayed Time to Pain and Function Worsening Compared to Placebo: Evaluation of Knee OA Symptom Progression Outcomes in a Phase 3 Trial (OA-07)
Abstract Number: 0909

Loss of MicroRNA29 expression in B cells and skin microbiota synergize to promote atopic dermatitis in mice.
Abstract Number: 0597

Low 25-hydroxyvitamin D Levels are Associated with Higher Mortality and More Cardiovascular Events in Systemic Lupus Erythematosus
Abstract Number: 0444

Low Disease Activity: Good Enough?
Abstract Number: 1543

Low-Dose Aspirin Therapy in Patients with Type 2 Diabetes and Systemic Lupus Erythematosus: A Propensity-Matched Cohort Study
Abstract Number: 0656

Low-dose belimumab reduced disease flares in patients with systemic lupus erythematosus at low disease activity: a multicenter, randomized, double-blind, placebo-controlled trial
Abstract Number: 0540

Low-Dose CT reveals syndesmophyte progression in axial SpA, particularly in the thoracic spine: Insights from the SPACE cohort covering early and established disease
Abstract Number: 1920

Lung Cancer Screening with Rheumatoid Arthritis: A Retrospective Claims Analysis
Abstract Number: 1193

Lung Transplant Outcomes in Patients with Myositis- and Systemic Sclerosis-Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis
Abstract Number: 2259

Lung Transplant Outcomes in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis and Meta-analysis
Abstract Number: 1255

Lung Transplantation Outcomes for Pulmonary Sarcoidosis Compared to Idiopathic Pulmonary Fibrosis: A Single Institution Multisite Experience
Abstract Number: 1580

Lung vasculature quantification on computed tomography predicts new onset of interstitial lung disease in systemic sclerosis
Abstract Number: 2387

Lupus Damage Index Revision – Item Generation and Reduction Phases
Abstract Number: 1503

Lupus Disease Activity Adversely Affects the Quality of Life but not Intimate Relationship and Sexual Function in Indian Female Lupus Patients
Abstract Number: 2455

Lupus Intervention Fatigue Trial: Preliminary Analysis of Baseline Data
Abstract Number: 1527

Lupus Nephritis Clinical Practice Guidelines: Critical Appraisal and Quality Comparison Using the AGREE II Tool
Abstract Number: 1082

Lupus Patient Navigator Program for Improving Care Adherence for Minority Patients
Abstract Number: 0985

Lupus Skin Shapes a Distinct Inflammatory Milieu that Drives the Skewing of Treg and inflammatory T cells
Abstract Number: 1485

Lupus Under the Lens: Fibrinogen-to-Albumin Ratio as a Novel Inflammatory Index
Abstract Number: 1681

Lymphoma and Other Malignancies in Sjögren’s Disease: Incidence, Predictive Factors, and Mortality Outcomes.

Jump to: View All • a b c d e f g h i j k [l] m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].